New hope for advanced GI cancer: targeted combo therapy enters phase 2
NCT ID NCT05934331
First seen Oct 31, 2025 · Last updated May 14, 2026 · Updated 31 times
Summary
This study tests a new drug called LM-302 combined with other cancer treatments for people with advanced gastrointestinal (GI) cancer that has a specific marker (CLDN18.2). The goal is to see if the combination can shrink tumors or slow cancer growth. About 276 adults aged 18-80 who have not responded to or cannot tolerate standard first-line therapy will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT NEOPLASMS OF DIGESTIVE ORGANS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai East Hospital
RECRUITINGShanghai, China
Contact
Conditions
Explore the condition pages connected to this study.